Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma

Clinical trial NCT06215651 · RECRUITING

Trial details

NCT number: NCT06215651
Sponsor: Peking Union Medical College Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Cadonilimab and Lenvatinib

Start date: 2024-03-11
Primary completion: 2025-01-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.